084650 — Labgenomics Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Market Cap
KR₩99bn
Enterprise Value
KR₩136bn
Revenue
KR₩88bn

Annual income statement for Labgenomics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	202,407	144,773	71,076	85,898	88,161
Cost of Revenue
Gross Profit	125,411	96,767	30,359	31,408	30,643
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	97,944	78,567	77,999	107,532	148,051
Operating Profit	104,463	66,206	-6,923	-21,633	-59,890
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	109,132	63,393	-7,133	-25,952	-60,259
Provision for Income Taxes
Net Income After Taxes	83,855	47,926	-5,291	-23,691	-64,375
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	83,855	48,397	-4,674	-23,796	-64,375
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	83,855	48,397	-4,674	-23,796	-64,375
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,246	715	-75.9	-290	-811
Dividends per Share